Neoantigen Cancer Vaccine Market: By Platform (mRNA, Peptide, DNA, Dendritic Cell, Viral Vector); Antigen Strategy (Individualized Neoantigen, Shared/Off-the-Shelf Antigen); Indication (Melanoma, Non-Small Cell Lung Cancer, Colorectal, Pancreatic, Renal Cell Carcinoma, Others); Treatment Line (Adjuvant / Minimal Residual Disease, Metastatic); End User (Hospitals & Cancer Centers, Specialty Clinics, Biopharma)—Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026–2035
The neoantigen cancer vaccine market is estimated at USD 250.7 million in 2025 and is projected to reach USD 9,027.2 million by 2035, growing at a CAGR of 43.1% over the forecast period 2026–2035. Read More
- Last Updated: 10-Sep-2026 | Format:
![pdf]()
![powerpoint]()
![excel]()
| Report ID: AA09261983
| Report ID: AA09261983Fill out the form below to receive a free sample of this report
Features | Type of License | ||||
 Data Book | Single User |   Multi User |  Corporate | ||
| e-Access | ✓ | ✓ | ✓ | ✓ | |
User Sharing | 1 User Only | 1 User Only | Up to 7 Users | Unlimited User Access | |
⨉ | ⨉ | ⨉ | ✓ | ||
Free Customization | No Free Customization | Up To 30 hrs work | Up To 60 hrs work | Up To 80 hrs work | |
Deliverable |
| ⨉ | ✓ | ✓ | ✓ |
| ✓ | ⨉ | ✓ | ✓ | |
| ⨉ | ⨉ | ⨉ | ✓ | |
Analyst Support | 2-Months Analyst Support | 4-Months Analyst Support | 7-Months Analyst Support | One Year Analyst Support | |
Free Report update in next update cycle | ⨉ | ⨉ | ⨉ | ✓ | |
Free Industry Update (Within 180 days) | ⨉ | ⨉ | ⨉ | ✓ | |
Benefit | Up to 10% off on Post Purchase | Up to 20% off on Post Purchase | Up to 30% off on Post Purchase | Up to 40% off on Post Purchase | |
